Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  IDEXX Laboratories, Inc.    IDXX

Delayed Quote. Delayed  - 02/11 03:59:58 pm
67.23 USD   -3.49%
02/01 IDEXX LABORATOR : Announces Fourth Quarter and Full Year 2015 Result..
01/29 IDEXX LABORATOR : beats Street 4Q forecasts
01/21 IDEXX LABORATOR : to Release 2015 Fourth Quarter and Full-Year Finan..
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

IDEXX Laboratories : Announces Fourth Quarter and Full Year 2015 Results

02/01/2016 | 09:38am US/Eastern

Release date- 29012016 - WESTBROOK, Maine - IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported revenues for the fourth quarter of 2015 of $400 million, an increase of 14%1 compared to the prior year period.

Normalized organic revenue growth2 for the quarter was over 11%, supported by strong growth in the Companion Animal Group ('CAG') segment. Revenue for the full year of $1,602 million increased 8% on a reported basis, supported by 11% normalized organic revenue growth.

Earnings per diluted share ('EPS') for the quarter was $0.48. Adjusted EPS growth3 was 2% compared to the prior year period, while absorbing a negative $0.03 per share impact related to net changes in foreign exchange, resulting in constant currency4 Adjusted EPS growth of 9%. The quarter benefited from recording the full year impact of the decision to make the federal research and development ('R&D') tax credit permanent, which had a $0.03 favorable impact on EPS, consistent with the prior year quarter.

'We were very pleased with the Company's performance in the fourth quarter, supported by record instrument placements in both North American and international markets. Total premium instrument placements were up 35% over a very strong prior year period, with Catalyst placements up 61% compared to last year. We achieved 694 Catalyst placements in North America and 868 in international markets, leveraging our expanded commercial presence globally.

In North America, 395 units or 57% of our Catalyst placements were to new and competitive accounts, up 37% over Q4 2014, a testament to the increasing effectiveness of our all-direct sales force. For the full year, we placed 9,771 chemistry and hematology instruments worldwide, substantially higher than any year in our history. SediVue Dx, our novel urine sediment analyzer for use in-clinic, and the recent regulatory approval of Catalyst One in Japan, will add to our already substantial momentum in placing instruments as we move through 2016,' said Jonathan Ayers, the Company's Chairman and Chief Executive Officer.

'SediVue is a breakthrough innovation that helps improve accuracy and streamlines workflows of a historically challenging manual process involving microscopic interpretation. SediVue presents veterinarians with a huge opportunity to enhance the quality of patient care while simultaneously helping to drive practice revenue growth and staff efficiency. Working in concert with chemistry and hematology, urinalysis forms the essential third pillar of the minimum diagnostic database in pet care,' continued Ayers.

'We also continue to be pleased by the enthusiastic response of our customers to IDEXX SDMA, our unique test for kidney disease, a common condition in pets. IDEXX SDMA has now been automatically added to all chemistry panels for customers in all of our major reference laboratory markets globally.

This novel kidney parameter is being well received globally by our customers, helped in part by the inclusion of SDMA in the International Renal Interest Society (IRIS) guidelines. IRIS is led by a board of 15 world-renowned independent veterinarians from 10 different countries, so the inclusion of SDMA as an important marker for renal function is a worldwide endorsement.' 'Our solid finish to 2015 is positioning us to deliver continued strong constant currency4 revenue and profit gains in 2016.

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 6,000 people and offers products to customers in over 175 countries.

Note Regarding Forward-Looking Statements

This earnings release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are included above under 'Financial Outlook for 2016' and elsewhere and can be identified by the use of words such as 'expects,' 'may,' 'anticipates,' 'intends,' 'would,' 'will,' 'plans,' 'believes,' 'estimates,' 'should,' and similar words and expressions.

Our forward-looking statements include statements relating to our revenue growth and EPS outlooks; free cash flow forecast; projected impact of foreign currency exchange rates; projected operating margins, capital expenditures, effective tax rate, weighted average shares outstanding and interest expense and projected product launches. These statements are based on management's expectation of future events as of the date of this earnings release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations.

Factors that could cause or contribute to such differences include the following: the Company's ability to successfully execute its strategy, including supporting its all-direct sales strategy in the US; the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; the Company's ability to achieve cost improvements in its worldwide network of laboratories and in the manufacture and service of in-clinic instruments; the Company's ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; disruptions, shortages or pricing changes that affect the Company's purchases of products and materials from third parties, including from sole source suppliers; the effectiveness of the Company's sales and marketing activities; the Company's ability to manufacture complex biologic products; the impact of a change to our relationship with the Company's distributors; the impact of distributor purchasing decisions on sales of the Company's products that are sold through distribution; the Company's ability to manage the risks associated with the use of distributors to sell the Company's products; the impact of increased competition from existing and new technologies and technological advances by our competitors; the promotion and sale of our competitors' products by our former US distribution partners; the effect of government regulation on the Company's business, including government decisions about whether and when to approve the Company's products and decisions regarding labeling, manufacturing and marketing products; the impact of veterinary hospital consolidation, and the prevalence of buying consortiums on the markets for the Company's products; the Company's ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; changes in testing patterns or practices in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; a failure or perceived failure to comply with regulations and our policies regarding the privacy and protection of user data; the effect of any strengthening of the rate of exchange for the US dollar; the effect of any adverse changes in the financial markets on the value of the Company's investment portfolio; the impact of a weak economy on demand for the Company's products and services or increased customer credit risk; the effects of operations outside the US, including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions and local business and cultural factors; the impact of the Company's limited experience and small scale in the human point-of-care market; the effects of interruptions to the Company's operations due to natural or man-made disasters, system failures or disruptions or security breaches; the effect on the Company's stock price if quarterly or annual operating results do not meet expectations of market analysts or investors in future periods; potential exposures related to our worldwide provision for income taxes and the potential loss of tax incentives and the Company's ability to obtain financing on favorable terms.

A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 and the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, in the sections captioned 'Risk Factors,' as well as the Company's other periodic reports filed or to be filed with the Securities and Exchange Commission.


Ed Garber


Investor Relations

Tel: 1-207-556-8155

(c) 2016 Electronic News Publishing -, source ENP Newswire

React to this article
02/01 IDEXX LABORATORIES : Announces Fourth Quarter and Full Year 2015 Results
01/29 IDEXX LABORATORIES : beats Street 4Q forecasts
01/29 IDEXX LABORATORIES : DE : Results of Operations and Financial Condition, Financi..
01/27 IDEXX LABORATORIES : Patent Issued for Compositions, Devices, Kits and Methods f..
01/25 IDEXX LABORATORIES : Assigned Patent
01/21 IDEXX LABORATORIES : to Release 2015 Fourth Quarter and Full-Year Financial Resu..
01/18 IDEXX LABORATORIES : Advances Cloud Technology Applications for Veterinary Profe..
01/14 IDEXX LABORATORIES : Patent Issued for Canine anti-CD20 Antibodies (USPTO 922800..
01/11 IDEXX LABORATORIES : U.S. Patents Awarded to Inventors in Maine (Jan. 11)
01/11 IDEXX LABORATORIES : Assigned Patent
News chart
Full-screen chart
Income Statement Evolution
More Financials